🇺🇸 Doxorubicina in United States

149 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Febrile Neutropenia — 40 reports (26.85%)
  2. Neutropenia — 19 reports (12.75%)
  3. Thrombocytopenia — 15 reports (10.07%)
  4. Pancytopenia — 14 reports (9.4%)
  5. Anaemia — 13 reports (8.72%)
  6. Drug Interaction — 13 reports (8.72%)
  7. Pyrexia — 12 reports (8.05%)
  8. Leukopenia — 9 reports (6.04%)
  9. Neuropathy Peripheral — 8 reports (5.37%)
  10. Hepatitis — 6 reports (4.03%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Doxorubicina approved in United States?

Doxorubicina does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Doxorubicina in United States?

Fondazione Italiana Linfomi - ETS is the originator. The local marketing authorisation holder may differ — check the official source linked above.